Prostaglandin E1 in pulmonary hypertension of collagen disease.
A 47-yr-old woman with low cardiac output and dyspnea due to pulmonary hypertension associated with rheumatoid arthritis was treated with two vasodilators. Although nicardipine, a Ca-channel blocking agent, reduced the pulmonary artery pressure (PAP), it reduced simultaneously the arterial BP, resulting in fluid retention with a low urine output and persistent high CVP. In contrast, prostaglandin E1 (PGE1) reduced successfully both the PAP and CVP. Although the BP decreased, a satisfactory urine output was maintained. The cardiac output increased from 3 to 4.5 L/min. PGE1 may help reduce reversible pulmonary hypertension of collagen disease.
D000527:Alprostadil / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications; D004417:Dyspnea / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged
D000527:Alprostadil